Beyond BCG: the potential for a more effective TB vaccine (Q33756046)

29 July 2017

1 reference

title

Beyond BCG: the potential for a more effective TB vaccine (English)

1 reference

29 July 2017

Orme IM

1 reference

29 July 2017

publication date

1 November 1999

1 reference

Trends in Molecular Medicine

29 July 2017

published in

1 reference

29 July 2017

1 reference

29 July 2017

1 reference

29 July 2017

page(s)

487-492

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901594-4

29 July 2017

1 reference

7 January 2021

Multidrug-resistant tuberculosis and its control

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901594-4

7 January 2021

Tuberculosis: commentary on a reemergent killer

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901594-4

7 January 2021

Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901594-4

7 January 2021

Assessment of worldwide tuberculosis control

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901594-4

7 January 2021

Tuberculosis in developing countries and methods for its control

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901594-4

7 January 2021

Pathogenesis of experimental tuberculosis in animal models

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901594-4

7 January 2021

An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901594-4

7 January 2021

Disseminated tuberculosis in interferon gamma gene-disrupted mice

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901594-4

7 January 2021

Adequate expression of protective immunity in the absence of granuloma formation in Mycobacterium tuberculosis-infected mice with a disruption in the intracellular adhesion molecule 1 gene.

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901594-4

7 January 2021

Criteria for discontinuation of vaccination programmes using Bacille Calmette-Guerin (BCG) in countries with a low prevalence of tuberculosis. A statement of the International Union Against Tuberculosis and Lung Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901594-4

7 January 2021

Pros and cons of BCG vaccination in countries with low incidence of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901594-4

7 January 2021

Is BCG vaccination against tuberculosis still indicated?

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901594-4

7 January 2021

BCG vaccination against tuberculosis: past disappointments and future hopes.

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901594-4

7 January 2021

BCG--mass or selective vaccination?

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901594-4

7 January 2021

The immunopathogenesis of tuberculosis: a new working hypothesis

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901594-4

7 January 2021

Immunogenicity and protective efficacy of a tuberculosis DNA vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901594-4

7 January 2021

Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901594-4

7 January 2021

Immunization of mice with mycobacterial culture filtrate proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901594-4

7 January 2021

Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901594-4

7 January 2021

Auxotrophic vaccines for tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901594-4

7 January 2021

BCG as a vector for the construction of multivalent recombinant vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901594-4

7 January 2021

Progress on development of the live BCG recombinant vaccine vehicle for combined vaccine delivery

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901594-4

7 January 2021

New use of BCG for recombinant vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901594-4

7 January 2021

Manipulation and potentiation of antimycobacterial immunity using recombinant bacille Calmette-Guérin strains that secrete cytokines

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901594-4

7 January 2021

Development of a BCG recombinant vehicle for candidate AIDS vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901594-4

7 January 2021

A Cocktail of Mycobacterium bovis BCG Recombinants Expressing the SIV Nef, Env, and Gag Antigens Induces Antibody and Cytotoxic Responses in Mice Vaccinated by Different Mucosal Routes

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901594-4

7 January 2021

Induction of a type 1 immune response to a recombinant antigen from Mycobacterium tuberculosis expressed in Mycobacterium vaccae

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901594-4

7 January 2021

CD1: presenting unusual antigens to unusual T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2899%2901594-4

7 January 2021

10.1016/S1357-4310(99)01594-4

Identifiers

DOI

1 reference

29 July 2017

1 reference